Lorlatinib

Lorlatinib Continuation Study

AQUA07 in Patients With ALK-Positive Non-Small Cell Lung Cancer

A Study to Learn About Patients With Non-Small Cell Lung Cancer (NSCLC) Who Took Lorlatinib as Their First Treatment

Testing the Addition of 131I-MIBG or Lorlatinib to Intensive Therapy in People With High-Risk Neuroblastoma (NBL)

Study of NXP900 With Lorlatinib in ALK+ Lung Cancer

A Study of Lorlatinib in Combination With Ramucirumab in People With Lung Cancer

A Study to Learn About Study Medicine Lorlatinib, as a First-line Treatment in Chinese Adults With ALK-positive a/mNSCLC

Lorlatinib Plus Sacituzumab Tirumotecan With Peripheral ctDNA Guidance as First-Line Therapy for ALK Fusion-Positive NSCLC

A Study to Learn About Lorlatinib in Patients With Non-Small Cell Lung Cancer (NSCLC) Which Has Spread Out.

Lorlatinib for Newly-Diagnosed High-Grade Glioma With ROS or ALK Fusion

A Study of Oral Lorlatinib in Patients With Relapsed ALK Positive Lymphoma

PF-07284892 in Participants With Advanced Solid Tumors

A Study of Lorlatinib in Subjects With ROS1-Positive Non-Small Cell Lung Cancer

Analysis of the Effectiveness and Safety of Lorlatinib in Untreated ALK-Positive NSCLC Patients in a French Real-World Context

Lorlatinib Plus Local Consolidation Therapy In ALK Positive Advanced Non-Small Cell Lung Cancer

Targeted Treatment for ALK Positive Patients Who Have Previously Been Treated for Non-squamous Non-small Cell Lung Cancer

Lorlatinib in Patients With ALK-Positive NSCLC With Brain or Leptomeningeal Metastases

A Study to Learn About Lorlatinib in Patients With Non-Small Cell Lung Cancer Which Could Not Be Controlled

Induction Lorlatinib in Stage III Non-small Cell Lung Cancer

A Study Of Lorlatinib Versus Crizotinib In First Line Treatment Of Patients With ALK-Positive NSCLC